Abstract:Medical cannabis is increasingly used as an alternative therapy for various conditions, including chronic pain, multiple sclerosis, epilepsy, and cancer-related symptoms. However, it is crucial to ensure that patients receive the intended dose of tetrahydrocannabinol (THC) from inhaled cannabis for optimal therapeutic effect without overdose risk. This requires a comprehensive understanding of the factors that influence the pharmacokinetics (PKs) of THC in the respiratory system. However, accurate estimation of lung dosimetry and blood concentration of inhaled THC remains challenging partially because the influence of diversified patient-specific puff patterns on inhaled THC transport, deposition, and translocation is still not well quantified. To address the knowledge gap mentioned above, this study employed a hybrid computational fluid-particle dynamics (CFPD) and pharmacokinetics (PK) model to evaluate factors that influence delivered doses of THC to the human respiratory system and the resultant THC-plasma concentration-time profile. Specifically, this study compared multiple puff waveforms for inhalation-holding-exhalation with total puff volumes from 55 to 82 ml, hold duration from 0 to 5 s, and three puff waveforms (i.e., square, sinusoidal, and realistic). THC deposition in the airways was recorded during all phases for each case using either 452,849 particles per second for the 1.128 μm monodisperse cases or 399,866 per second for the polydisperse cases, with the mass median aerodynamic diameter (MMAD) of 1.128 μm. Pulmonary air-THC particle transport dynamics, THC particle deposition data, and THC vapor absorption are predicted using CFPD for four airway regions, then scaled by region-specific bioavailability factors. The deposited THC mass in airway regions represents the initial mass entering a 3-compartment PK model, which was employed to predict the THC-plasma concentration-time profiles. The CFPD-PK results revealed significant variability in THC transport, deposition, and plasma concentration based on IHE factors. Specifically, larger puff volumes and longer holding times enhanced THC deposition in deeper airways and increased plasma concentrations. Realistic transient puff waveforms predicted higher particle deposition and THC concentrations than simplified square waveforms. Polydisperse particle distributions showed more realistic deposition patterns than monodisperse simulations. This study provides insights into the complexity of THC inhalation therapy, emphasizing the importance of considering individualized puff patterns and realistic particle size distributions in accurately predicting therapeutic outcomes, which is highly related to THC deposition in the lung and THC plasma concentration. These findings and the CFPD-PK modeling framework offer guidance for clinicians in prescribing personalized THCdosages, support regulatory science in evaluating inhalation devices, and contribute to ongoing research aimed at optimizing THCdelivery for maximum therapeutic benefit while minimizing potential overdose risks.

Simulated pharmacokinetics of inhaled caffeine and melatonin from existing products indicate the lack of dosimetric considerations

Adenosine, caffeine, and sleep–wake regulation: state of the science and perspectives

Influence of Caffeine on the Sedative Effects of Promethazine Based on Pharmacokinetics and Metabolomics

Alteration of intracerebral metabolites and subjective sleepiness by acute caffeine administration in adults

Assessing the potential impact of age and inhalant use on sleep in adolescents

Comparative Pharmacokinetics of Sustained-Release versus Immediate-Release Melatonin Capsules in Fasting Healthy Adults: A Randomized, Open-Label, Cross-Over Study

Concentration–effect relationships of plasma caffeine on EEG delta power and cardiac autonomic activity during human sleep

Estimating human pharmacokinetic parameters forelectronic nicotine delivery system products from chemical analyses of their aerosols

Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption

Sleep-Aids Derived from Natural Products

Respiratory Safety Pharmacological Testing with Single Intravenous Administration of Caffeine in Sprague–Dawley Rats

Pharmacokinetic Profile of Caffeine and Its Two Main Metabolites in Dried Blood Spots After Five Different Oral Caffeine Administration Forms—A Randomized Crossover Study

Community-based causal evidence that high habitual caffeine consumption alters distinct polysomnography-derived sleep variables

CFPD-PK simulation of inhaled Delta-9-tetrahydrocannabinol aerosol dynamics: Transport, deposition, and translocation in a mouth-to-G10 subject-specific human airway

Caffeine-dependent changes of sleep-wake regulation: evidence for adaptation after repeated intake

Melatonin Use in School-Aged Children and Adolescents: An Exploration of Caregiver and Pharmacist Perspectives

Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model

Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: nicotine delivery systems and beyond

Pharmacological Modulation of Sleep Homeostasis in Rat: Novel Effects of an mGluR2/3 Antagonist

Respiratory Responses to a Single Oral Dose of Caffeine in Male Sprague-Dawley Rats

Numerical Study on the Effect of the Realistic Mouth-Inhaler Positions on Orally Inhaled Drug Delivery in Pediatric Intersubject Upper Airways